Connecticut Statutes
§ 17b-491b — Reimbursement formula for drugs used to treat hemophilia A.
The maximum allowable cost paid for antihemophilic Factor VII, VIII, IX and X products under the Medicaid program shall be the actual acquisition cost as reflected on the manufacturer's invoice plus eight per cent plus the professional dispensing fee established for covered outpatient drugs.
Free access — add to your briefcase to read the full text and ask questions with AI
Connecticut § 17b-491b (Reimbursement formula for drugs used to treat hemophilia A.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.
Legislative History
(June Sp. Sess. P.A. 00-2, S. 35, 53; P.A. 04-76, S. 22; P.A. 11-44, S. 131; P.A. 13-234, S. 100; June Sp. Sess. P.A. 17-2, S. 200.) History: June Sp. Sess. P.A. 00-2 effective July 1, 2000; P.A. 04-76 deleted reference to “general assistance”; P.A. 11-44 deleted “state-administered general assistance”, effective July 1, 2011; P.A. 13-234 deleted reference to ConnPACE program, effective January 1, 2014; June Sp. Sess. P.A. 17-2 deleted provision re Factor VIII pharmaceuticals, added “antihemophilic Factor VII, VIII, IX and X products”, added reference to manufacturer's invoice re acquisition cost and added “plus the professional dispensing fee established for covered outpatient drugs”, effective October 31, 2017.
Nearby Sections
15
§ 17b-102
(Formerly Sec. 17-83n). Regulations providing a financial incentive for reporting vendor fraud.§ 17b-103
(Formerly Sec. 17-83p). Refunds by vendors to persons eligible for medical assistance. Penalty.§ 17b-105
(Formerly Sec. 17-2d). Authority to furnish transportation out of state for recipients of aid.§ 17b-105e
Definitions.